MCID: ENC004
MIFTS: 66

Encephalitis

Categories: Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Encephalitis

Summaries for Encephalitis

NINDS : 55 Meningitis is an infection of the meninges, the membranes that surround the brain and spinal cord. Encephalitis is inflammation of the brain itself. Anyone can get encephalitis or meningitis. Causes of encephalitis and meningitis include viruses, bacteria, fungus, and parasites. Anyone experiencing symptoms of meningitis or encephalitis should see a doctor immediately. Symptoms of encephalitis that might require emergency treatment include loss of consciousness, seizures, muscle weakness, or sudden severe dementia. Other symptoms include: sudden fever, headache, vomiting, heightened sensitivity to light, stiff neck and back, confusion and impaired judgment, drowsiness, weak muscles, a clumsy and unsteady gait, irritability. In more severe cases, people may have problems with speech or hearing, vision problems, and hallucinations. Symptoms of meningitis, which may appear suddenly, often include: high fever, severe and persistent headache, stiff neck, nausea, sensitivity to bright light, vomiting, and changes in behavior such as confusion, sleepiness, and difficulty waking up. In infants, symptoms of meningitis or encephalitis may include fever, vomiting, lethargy, body stiffness, unexplained irritability, and a full or bulging fontanel (the soft spot on the top of the head).

MalaCards based summary : Encephalitis is related to tick-borne encephalitis and herpes simplex encephalitis, and has symptoms including seizures, tremor and back pain. An important gene associated with Encephalitis is UNC93B1 (Unc-93 Homolog B1, TLR Signaling Regulator), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Prednisone and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and testes, and related phenotypes are no effect and hematopoietic system

Disease Ontology : 12 A brain disease that is characterized as an acute inflammation of the brain with flu-like symptoms.

MedlinePlus : 44 Encephalitis is an inflammation of the brain. Usually the cause is a viral infection, but bacteria can also cause it. It can be mild or severe. Most cases are mild. You may have flu-like symptoms. With a mild case, you may just need rest, plenty of fluids, and a pain reliever. Severe cases need immediate treatment. Symptoms of severe cases include Severe headache Sudden fever Drowsiness Vomiting Confusion Seizures In babies, additional symptoms may include constant crying, poor feeding, body stiffness, and bulging in the soft spots of the skull. Severe cases may require a stay in the hospital. Treatments include oral and intravenous (IV) medicines to reduce inflammation and treat infection. Patients with breathing difficulties may need artificial respiration. Some people may need physical, speech, and occupational therapy once the illness is under control. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 77 Encephalitis is inflammation of the brain. Severity is variable. Symptoms may include headache, fever,... more...

Related Diseases for Encephalitis

Diseases in the Encephalitis family:

Viral Encephalitis Autoimmune Encephalitis

Diseases related to Encephalitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 781)
# Related Disease Score Top Affiliating Genes
1 tick-borne encephalitis 34.3 CCR5 CD209 CXCL10 TLR3
2 herpes simplex encephalitis 34.1 IRF3 TICAM1 TLR3 TRAF3 UNC93B1
3 viral encephalitis 33.8 CCL2 CCL5 CXCL10 IL1B
4 japanese encephalitis 33.8 CCL5 CD209 CLEC4G CLEC4M CXCL10 DDX58
5 west nile virus 32.6 CCR5 CD209 CLEC4M DDX58 IRF3 RSAD2
6 malaria 31.5 CCL2 CCL5 CXCL10 CXCL9 IL1B
7 herpes simplex 31.5 CD209 DDX58 IRF3 TICAM1 TLR3 TRAF3
8 dengue virus 30.9 CD209 DDX58 RPSA RSAD2
9 measles 30.8 CD209 DDX58 TLR3
10 rabies 30.8 CCL5 CXCL10 IRF3 TLR3
11 influenza 30.6 CCL5 DDX58 IRF3 RSAD2 TLR3
12 yellow fever 30.6 CCL2 CCL5 CCR5 RSAD2
13 mouth disease 30.5 IL1B IRF3 TLR3
14 noonan syndrome 3 30.4 DDX58 IRF3 RSAD2 TLR3
15 viral meningitis 30.4 CCL2 CCL5 CXCL10
16 stomatitis 30.4 DDX58 IL1B RSAD2
17 chikungunya 30.3 CCL2 CCL5 DDX58 IL1B RSAD2
18 opsoclonus-myoclonus syndrome 30.2 CXCL10 CXCL9
19 pneumonia 30.2 CCL2 CCL5 IL1B
20 trypanosomiasis 30.1 CCL2 CCL5 IL1B
21 lymphadenitis 30.0 CD209 CXCL9 IL1B
22 neuritis 29.9 AQP4 CCL2 CCL5 CXCL10 IL1B
23 cerebral hemorrhage 29.9 GFAP IL1B
24 cytomegalovirus infection 29.8 CCL2 CCL5 IL1B IRF3
25 hepatitis c 29.7 CLEC4M CXCL10 DDX58 IRF3 TLR3
26 human immunodeficiency virus type 1 29.6 CCL2 CCL5 CCR5 CD209 CLEC4M CXCL10
27 hepatitis c virus 29.6 CCR5 CLEC4M DDX58 IRF3 RSAD2
28 demyelinating disease 29.5 AQP4 CCL2 CCL5 CXCL10 IL1B
29 pulmonary sarcoidosis 29.5 CCL2 CCL5 CCR5
30 chagas disease 29.4 CCL2 CCR5 IL1B
31 multiple sclerosis 29.4 AQP4 CCL2 CCL5 CCR5 CXCL10 GFAP
32 severe acute respiratory syndrome 29.1 CCL2 CCL5 CD209 CLEC4M CXCL10 IRF3
33 viral infectious disease 29.0 CCL5 CCR5 CD209 CXCL10 DDX58 IL1B
34 nervous system disease 29.0 AQP4 CCL2 GFAP IL1B
35 central nervous system disease 28.7 AQP4 CCL2 CCR5 GFAP IL1B
36 la crosse encephalitis 12.6
37 st. louis encephalitis 12.6
38 eastern equine encephalitis 12.6
39 limbic encephalitis 12.5
40 western equine encephalitis 12.5
41 rasmussen encephalitis 12.5
42 murray valley encephalitis 12.5
43 granulomatous amebic encephalitis 12.4
44 west nile encephalitis 12.4
45 autoimmune encephalitis 12.4
46 venezuelan equine encephalitis 12.4
47 powassan encephalitis 12.4
48 meningitis and encephalitis 12.4
49 limbic encephalitis with lgi1 antibodies 12.4
50 hhv-6 encephalitis 12.4

Graphical network of the top 20 diseases related to Encephalitis:



Diseases related to Encephalitis

Symptoms & Phenotypes for Encephalitis

UMLS symptoms related to Encephalitis:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Encephalitis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 AQP4 CCL2 CCL5 CCR5 CD209 CLEC4G

MGI Mouse Phenotypes related to Encephalitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 AQP4 CCL5 CCR5 CLEC4G CLEC4M CXCL10
2 homeostasis/metabolism MP:0005376 10 AQP4 CCR5 CLEC4G CLEC4M CXCL10 DDX58
3 immune system MP:0005387 9.86 AQP4 CCL2 CCL5 CCR5 CLEC4G CLEC4M
4 mortality/aging MP:0010768 9.44 AQP4 CCR5 CLEC4M CXCL10 DDX58 GFAP

Drugs & Therapeutics for Encephalitis

Drugs for Encephalitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 272)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Azithromycin Approved Phase 4,Phase 1 83905-01-5 55185 447043
3
Sulfadiazine Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 68-35-9 5215
4
Sulfamethoxazole Approved Phase 4 723-46-6 5329
5
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 58-14-0 4993
6
leucovorin Approved Phase 4,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
7
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
8
Formaldehyde Approved, Vet_approved Phase 4,Phase 3 50-00-0 712
9
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
10
Minocycline Approved, Investigational Phase 4,Phase 1 10118-90-8 5281021
11
Dimenhydrinate Approved Phase 4 523-87-5 441281
12
Emtricitabine Approved, Investigational Phase 4,Phase 2 143491-57-0 60877
13
Natalizumab Approved, Investigational Phase 4 189261-10-7
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 83-43-2 6741
15
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Not Applicable 2921-57-5
16
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-24-8 5755
17
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Not Applicable 302-25-0
18
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
19
Racepinephrine Approved Phase 4 329-65-7 838
20
Dolutegravir Approved Phase 4 1051375-16-6 54726191
21
Abacavir Approved, Investigational Phase 4 136470-78-5 441300 65140
22
Cobicistat Approved Phase 4 1004316-88-4
23
Lamivudine Approved, Investigational Phase 4,Phase 2 134678-17-4 60825
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 59-30-3 6037
25
Lactitol Investigational Phase 4,Phase 3,Phase 2 585-86-4, 585-88-6 493591
26
Tenofovir Experimental, Investigational Phase 4,Phase 2 147127-20-6 464205
27
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Not Applicable 2920-86-7
28 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Epoetin alfa Phase 4 113427-24-0
33 Hematinics Phase 4
34 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
35 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
36 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
37 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
38 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Anti-Retroviral Agents Phase 4,Phase 1,Phase 2,Not Applicable
42 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Anti-HIV Agents Phase 4,Phase 1,Phase 2,Not Applicable
44 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antibodies, Blocking Phase 4,Phase 3,Phase 2
46 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
47 Vitamin B Complex Phase 4,Phase 2,Phase 1,Not Applicable
48 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
49 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 334)
# Name Status NCT ID Phase Drugs
1 Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Unknown status NCT01954810 Phase 4
2 Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients Unknown status NCT03004209 Phase 4 Erythropoietin
3 The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
4 Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX Completed NCT02526550 Phase 4
5 A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 Completed NCT01656200 Phase 4
6 Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj Completed NCT02532569 Phase 4
7 Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age Completed NCT00463684 Phase 4
8 Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Completed NCT02643433 Phase 4
9 Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Completed NCT01567865 Phase 4
10 Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Completed NCT01562444 Phase 4
11 6-year Antibody Check After Third Vaccination Against Japanese Encephalitis Completed NCT02039440 Phase 4
12 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
13 TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209) Completed NCT00161967 Phase 4
14 An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE Completed NCT01106482 Phase 4
15 Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401) Completed NCT00894686 Phase 4
16 Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose Completed NCT02514746 Phase 4
17 Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine Completed NCT01398540 Phase 4
18 This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population Completed NCT01158599 Phase 4
19 TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223) Completed NCT00503529 Phase 4
20 Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac Completed NCT01710189 Phase 4 TicoVac
21 Treatment of Cerebral Toxoplasmosis in HIV/AIDS Completed NCT00367081 Phase 4 TMX-SMX (Bactrim(R));Pyrimethamine plus Sulfadiazine plus leucoverin
22 Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years Completed NCT00161954 Phase 4
23 Post-licensure Safety Study of IMOJEV® in Thailand Completed NCT01981967 Phase 4
24 Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination Completed NCT00804219 Phase 4
25 Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults Completed NCT00311493 Phase 4
26 Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children Completed NCT00311441 Phase 4
27 TBE Seropersistence up to 10 Years After First Booster in Adults Completed NCT01582698 Phase 4
28 Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225) Completed NCT00163540 Phase 4
29 Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults Completed NCT00387634 Phase 4
30 Influence of Persistent CMV-infection on Immune Senescence Completed NCT00461695 Phase 4
31 Immunogenicity of SA 14-14-2 JE Vaccine Completed NCT01635816 Phase 4
32 Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years Completed NCT00452621 Phase 4
33 Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years Completed NCT00161785 Phase 4
34 Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine Completed NCT01815073 Phase 4
35 Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun® Completed NCT02511587 Phase 4
36 Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events Completed NCT01417949 Phase 4
37 Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults Completed NCT02062281 Phase 4
38 Minocycline to Treat Childhood Regressive Autism Completed NCT00409747 Phase 4 Minocycline
39 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
40 TBE Vaccination in Allergic Patients Completed NCT02511535 Phase 4
41 A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults Completed NCT01427309 Phase 4
42 SOLFAMU Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies Recruiting NCT02951559 Phase 4
43 Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine Recruiting NCT03519568 Phase 4
44 A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Recruiting NCT03067285 Phase 4 ELV/COBI/FTC/TAF;DTG/3TC/ABC + ELV/COBI/FTC/TAF
45 The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine Active, not recruiting NCT03294135 Phase 4
46 Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide Active, not recruiting NCT01970410 Phase 4 teriflunomide
47 The Phase IVd of Inactivated Enterovirus 71 Vaccine Enrolling by invitation NCT03296410 Phase 4
48 IHPOTOTAM : Induced HyPOthermia TO Treat Adult Meningitis Terminated NCT00774631 Phase 4
49 Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) Terminated NCT01211665 Phase 4 Methylprednisolone;Prednisolone
50 A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children Withdrawn NCT03192371 Phase 4

Search NIH Clinical Center for Encephalitis

Cochrane evidence based reviews: encephalitis

Genetic Tests for Encephalitis

Genetic tests related to Encephalitis:

# Genetic test Affiliating Genes
1 Encephalitis 30

Anatomical Context for Encephalitis

MalaCards organs/tissues related to Encephalitis:

42
Brain, T Cells, Testes, Kidney, Lung, B Cells, Temporal Lobe

Publications for Encephalitis

Articles related to Encephalitis:

(show top 50) (show all 11832)
# Title Authors Year
1
Leucine-Rich Glioma-Inactivated Protein 1 Antibody-Positive Limbic Encephalitis in a Patient with Adenocarcinoma of Prostate: A Case Report. ( 30692776 )
2019
2
Anti-Amphiphysin-associated limbic encephalitis in a 72-year-old patient with aortic angiosarcoma. ( 30872337 )
2019
3
Serological Evidence of Tick-Borne Encephalitis and West Nile Virus Infections Among Children with Arthritis in Turkey. ( 30688547 )
2019
4
Diagnostic response to a cross-border challenge for the Swiss caprine arthritis encephalitis virus eradication program. ( 30696612 )
2019
5
Fulminant Subacute Sclerosing Panencephalitis Mimicking Autoimmune Encephalitis. ( 30762710 )
2019
6
A transdiagnostic pattern of psychiatric symptoms in autoimmune encephalitis. ( 30765327 )
2019
7
A Rasmussen encephalitis, autoimmune encephalitis, and mitochondrial disease mimicker: expanding the DNM1L-associated intractable epilepsy and encephalopathy phenotype. ( 30767894 )
2019
8
A clinical TRIAD for early suspicion of autoimmune encephalitis as a possibility in patients presenting with progressive cognitive decline. ( 30836326 )
2019
9
Editorial: Emerging Challenges in the Diagnosis and Treatment of Autoimmune Encephalitis. ( 30858821 )
2019
10
Autoimmune encephalitis: frequency and prognosis. ( 30877379 )
2019
11
Immune-Checkpoint-Inhibitor-Induced Severe Autoimmune Encephalitis Treated by Steroid and Intravenous Immunoglobulin. ( 30877699 )
2019
12
An Assay to Determine Mechanisms of Rapid Autoantibody-Induced Neurotransmitter Receptor Endocytosis and Vesicular Trafficking in Autoimmune Encephalitis. ( 30881339 )
2019
13
Atypical Autoimmune Encephalitis With Neuropil Antibodies Against a Yet Unknown Epitope. ( 30891000 )
2019
14
Commentary: Detection Methods for Autoantibodies in Suspected Autoimmune Encephalitis. ( 30915021 )
2019
15
Admission diagnoses of patients later diagnosed with autoimmune encephalitis. ( 30421340 )
2019
16
Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment. ( 30568992 )
2019
17
An evolving redefinition of autoimmune encephalitis. ( 30572142 )
2019
18
Prognosticating autoimmune encephalitis: A systematic review. ( 30595145 )
2019
19
Autoimmune encephalitis: A costly condition. ( 30674590 )
2019
20
Development of the Clinical Assessment Scale in Autoimmune Encephalitis (CASE). ( 30675918 )
2019
21
Diagnosing autoimmune encephalitis based on clinical features and autoantibody findings. ( 30676128 )
2019
22
Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report. ( 30680206 )
2019
23
Antibody-LGI 1 autoimmune encephalitis manifesting as rapidly progressive dementia and hyponatremia: a case report and literature review. ( 30732585 )
2019
24
Sleep disturbances are common in patients with autoimmune encephalitis. ( 30741377 )
2019
25
Autoimmune Encephalitis Secondary to Melanoma. ( 30743260 )
2019
26
An overlapping case of Bickerstaff brainstem encephalitis and acute motor axonal neuropathy variant of Guillain-Barré syndrome associated with systemic lupus erythematosus. ( 30444497 )
2019
27
Balint syndrome in anti-NMDA receptor encephalitis. ( 30588484 )
2019
28
Long-term Sequelae of Pediatric Bickerstaff Brainstem Encephalitis Includes Autonomic and Sleep Dysregulation. ( 30604651 )
2019
29
Fulminant thymomatous AMPAR-antibody limbic encephalitis with hypertonic coma, bruxism, an isoelectric electroencephalogram and temporal cortical atrophy, with recovery. ( 30796080 )
2019
30
Transient splenial hyperintensity in a rare case of chikungunya encephalitis. ( 30860134 )
2019
31
Progressive Dementia Revealing an Atypical Encephalitis: Neuroimaging Aspects. ( 30848988 )
2019
32
Dengue virus is an under-recognised causative agent of acute encephalitis syndrome (AES): Results from a four year AES surveillance study of Japanese encephalitis in selected states of India. ( 30641206 )
2019
33
Aerosol infection of Balb/c mice with eastern equine encephalitis virus; susceptibility and lethality. ( 30611287 )
2019
34
Rational design of a live-attenuated eastern equine encephalitis virus vaccine through informed mutation of virulence determinants. ( 30742691 )
2019
35
Complex Epidemiological Dynamics of Eastern Equine Encephalitis Virus in Florida. ( 30860014 )
2019
36
Japanese Encephalitis Virus in Australia: From Known Known to Known Unknown. ( 30791674 )
2019
37
Cell-Free Mitochondrial DNA in the CSF: A Potential Prognostic Biomarker of Anti-NMDAR Encephalitis. ( 30792710 )
2019
38
Novel RU486 (mifepristone) analogues with increased activity against Venezuelan Equine Encephalitis Virus but reduced progesterone receptor antagonistic activity. ( 30796232 )
2019
39
Parkinsonism Caused by Viral Encephalitis Affecting the Bilateral Substantia Nigra. ( 30796493 )
2019
40
Implementation of preventive measures against tick-borne infections in a non-endemic area for tick-borne encephalitis-Results from a population-based survey in Lower Saxony, Germany. ( 30797728 )
2019
41
Next-generation sequencing combined with routine methods to detect the pathogens of encephalitis/meningitis from a Chinese tertiary pediatric neurology center. ( 30797792 )
2019
42
A nationwide survey of norovirus-associated encephalitis/encephalopathy in Japan. ( 30798941 )
2019
43
Cerebral Venous Thrombosis as Rare Presentation of Herpes Simplex Virus Encephalitis. ( 30800483 )
2019
44
Anti-MOG encephalitis mimicking small vessel CNS vasculitis. ( 30800721 )
2019
45
Proton magnetic resonance spectroscopy (1H-MRS) of the brain in patients with tick-borne encephalitis. ( 30808997 )
2019
46
Clinico-epidemiological Study of Viral Acute Encephalitis Syndrome Cases and Comparison to Nonviral Cases in Children from Eastern India. ( 30814829 )
2019
47
A case of West Nile virus encephalitis accompanied by diabetic ketoacidosis and rhabdomyolysis. ( 30815360 )
2019
48
Molecular interaction of the antiviral compound CW‑33 and its analogues with the NS2B‑NS3 protease of the Japanese encephalitis virus. ( 30816489 )
2019
49
Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial. ( 30833160 )
2019
50
Will dual Japanese encephalitis and measles-rubella vaccination hinder measles and rubella eradication? ( 30833161 )
2019

Variations for Encephalitis

ClinVar genetic disease variations for Encephalitis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ABCD1 NM_000033.3(ABCD1): c.1866-1G> C single nucleotide variant Likely pathogenic rs1557055311 GRCh37 Chromosome X, 153008674: 153008674
2 ABCD1 NM_000033.3(ABCD1): c.1866-1G> C single nucleotide variant Likely pathogenic rs1557055311 GRCh38 Chromosome X, 153743220: 153743220

Expression for Encephalitis

Search GEO for disease gene expression data for Encephalitis.

Pathways for Encephalitis

Pathways related to Encephalitis according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 CCL2 CCL5 CCR5 CD209 CXCL10 DDX58
2
Show member pathways
13.32 CCL2 CCL5 CCR5 CXCL10 CXCL9 IL1B
3
Show member pathways
13.27 CCL2 CCL5 CCR5 CXCL10 DDX58 IL1B
4
Show member pathways
13 CCL2 CCL5 CXCL10 CXCL9 IL1B IRF3
5
Show member pathways
12.82 CCL2 CCL5 CCR5 DDX58 IL1B IRF3
6
Show member pathways
12.79 CCL2 CCL5 CCR5 CXCL10 CXCL9
7
Show member pathways
12.52 IL1B IRF3 TICAM1 TLR3 TRAF3
8
Show member pathways
12.52 CCL5 CXCL10 DDX58 IL1B IRF3 TICAM1
9
Show member pathways
12.33 DDX58 IRF3 TICAM1 TLR3
10
Show member pathways
12.23 CCL2 CXCL10 IL1B TRAF3
11
Show member pathways
12.21 IL1B IRF3 TICAM1 TLR3
12 12.17 CCL2 CCL5 CXCL10 DDX58 IL1B IRF3
13
Show member pathways
12.16 IRF3 TICAM1 TLR3 TRAF3
14
Show member pathways
12.14 CCL2 CCL5 CCR5 CXCL10 CXCL9 IL1B
15 11.95 AQP4 CCL2 CXCL10 GFAP IL1B
16
Show member pathways
11.92 CCL2 CCL5 CCR5 CXCL10 CXCL9
17
Show member pathways
11.88 CCL2 CCL5 CD209 CLEC4M CXCL10 DDX58
18 11.87 CCL2 CCL5 CXCL10 IL1B TRAF3
19 11.83 DDX58 IL1B TICAM1 TRAF3
20 11.76 CCL2 CCL5 IL1B
21 11.66 IL1B IRF3 TICAM1
22 11.65 CCL2 CCL5 CXCL10 CXCL9 IL1B
23 11.56 CCL2 CCL5 IL1B
24 11.31 CXCL10 CXCL9 IL1B
25 11.24 CCL2 CCL5 CCR5 CXCL10 IL1B
26 11.15 CCL2 CCL5 CXCL10 CXCL9 IL1B
27 10.94 CCL2 CCL5 CXCL10 CXCL9 GFAP IL1B
28 10.84 CCL2 IL1B

GO Terms for Encephalitis

Cellular components related to Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 AQP4 CCR5 CD209 CXCL10 CXCL9
2 host cell GO:0043657 8.96 CD209 CLEC4M

Biological processes related to Encephalitis according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.99 CCL5 CCR5 CXCL10 CXCL9 IL1B
2 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.97 IL1B IRF3 TICAM1 TLR3
3 response to lipopolysaccharide GO:0032496 9.97 CXCL10 IL1B IRF3 TICAM1
4 defense response GO:0006952 9.96 CCR5 CXCL10 CXCL9 TLR3
5 chemotaxis GO:0006935 9.95 CCL2 CCL5 CCR5 CXCL10 CXCL9
6 response to bacterium GO:0009617 9.92 CCL2 CXCL10 CXCL9 IRF3
7 inflammatory response GO:0006954 9.92 CCL2 CCL5 CCR5 CXCL10 CXCL9 IL1B
8 response to virus GO:0009615 9.91 CCL5 CXCL10 DDX58 RSAD2 TLR3
9 innate immune response GO:0045087 9.91 CD209 CLEC4M DDX58 IRF3 RSAD2 TICAM1
10 cellular response to interferon-gamma GO:0071346 9.9 AQP4 CCL2 CCL5 TLR3
11 cell chemotaxis GO:0060326 9.88 CCL2 CCL5 CCR5 CXCL10
12 viral entry into host cell GO:0046718 9.88 CD209 CLEC4G CLEC4M RPSA
13 neutrophil chemotaxis GO:0030593 9.88 CCL2 CCL5 CXCL10 CXCL9 IL1B
14 cellular response to organic cyclic compound GO:0071407 9.87 CCL2 CCL5 IL1B
15 positive regulation of T cell proliferation GO:0042102 9.86 CCL5 CD209 IL1B
16 positive regulation of interleukin-6 production GO:0032755 9.86 DDX58 IL1B TICAM1 TLR3
17 protein kinase B signaling GO:0043491 9.83 CCL2 CCL5 IL1B
18 chemokine-mediated signaling pathway GO:0070098 9.83 CCL2 CCL5 CCR5 CXCL10 CXCL9
19 toll-like receptor signaling pathway GO:0002224 9.82 TLR3 TRAF3 UNC93B1
20 positive regulation of type I interferon production GO:0032481 9.82 IRF3 TICAM1 TLR3
21 response to exogenous dsRNA GO:0043330 9.8 DDX58 IRF3 TICAM1 TLR3
22 leukocyte cell-cell adhesion GO:0007159 9.79 CCL5 CD209 CLEC4M
23 positive regulation of interleukin-8 production GO:0032757 9.79 DDX58 IL1B TLR3
24 positive regulation of interferon-beta production GO:0032728 9.78 DDX58 IRF3 TLR3
25 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.76 IRF3 TICAM1 TLR3 TRAF3
26 viral genome replication GO:0019079 9.74 CCL2 CD209 CLEC4M
27 necroptotic process GO:0070266 9.72 TICAM1 TLR3
28 positive regulation of cAMP-mediated signaling GO:0043950 9.72 CXCL10 CXCL9
29 positive regulation of monocyte chemotaxis GO:0090026 9.72 CCL5 CXCL10
30 dendritic cell chemotaxis GO:0002407 9.72 CCL5 CCR5
31 positive regulation of glial cell proliferation GO:0060252 9.72 GFAP IL1B
32 cellular response to exogenous dsRNA GO:0071360 9.71 DDX58 TLR3
33 positive regulation of T cell migration GO:2000406 9.71 CCL5 CXCL10
34 macrophage chemotaxis GO:0048246 9.71 CCL2 CCL5
35 positive regulation of interferon-alpha production GO:0032727 9.71 DDX58 IRF3
36 intracellular transport of virus GO:0075733 9.71 CD209 CLEC4M
37 toll-like receptor 3 signaling pathway GO:0034138 9.71 TICAM1 TLR3 UNC93B1
38 MyD88-independent toll-like receptor signaling pathway GO:0002756 9.7 TICAM1 TLR3
39 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.7 DDX58 IL1B
40 positive regulation of chemokine biosynthetic process GO:0045080 9.7 IL1B TICAM1 TLR3
41 positive regulation of interferon-beta biosynthetic process GO:0045359 9.69 TICAM1 TLR3
42 modulation by virus of host morphology or physiology GO:0019048 9.68 CD209 CLEC4M
43 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.68 TICAM1 TLR3
44 cell-cell recognition GO:0009988 9.68 CD209 CLEC4M
45 positive regulation of myeloid dendritic cell cytokine production GO:0002735 9.67 DDX58 TICAM1
46 detection of virus GO:0009597 9.66 DDX58 TLR3
47 virion attachment to host cell GO:0019062 9.66 CD209 CLEC4M
48 peptide antigen transport GO:0046968 9.64 CD209 CLEC4M
49 lipopolysaccharide-mediated signaling pathway GO:0031663 9.55 CCL2 CCL5 IL1B IRF3 TICAM1
50 cellular response to lipopolysaccharide GO:0071222 9.5 CCL2 CCR5 CXCL10 CXCL9 IL1B IRF3

Molecular functions related to Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.55 CCL2 CCL5 CXCL10 CXCL9 IL1B
2 virion binding GO:0046790 9.37 CD209 CLEC4M
3 CXCR3 chemokine receptor binding GO:0048248 9.26 CXCL10 CXCL9
4 chemokine activity GO:0008009 9.26 CCL2 CCL5 CXCL10 CXCL9
5 virus receptor activity GO:0001618 9.02 CCR5 CD209 CLEC4G CLEC4M RPSA
6 protein binding GO:0005515 10.25 AQP4 CCL2 CCL5 CCR5 CD209 CLEC4G

Sources for Encephalitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....